The last two decades have witnessed a steadily growing interest for organometallic compounds in medicinal chemistry and chemical biology. 1 The unique properties of metal complexes such as structural diversity, adjustable ligand exchange kinetics, finetuned redox activities, photoreactivity, the availability of radioisotopes, and distinct spectroscopic signatures make them highly versatile scaffolds for the modulation, sensing, and imaging of biological processes. complexes, for example, can serve as highly potent and selective inhibitors of protein kinases and lipid kinases. 7 We believe that especially octahedral coordination modes offer new opportunities to design globular and well-defined molecular shapes that can fill protein pockets such as enzyme active sites in unique ways.
' INTRODUCTION
The last two decades have witnessed a steadily growing interest for organometallic compounds in medicinal chemistry and chemical biology. 1 The unique properties of metal complexes such as structural diversity, adjustable ligand exchange kinetics, finetuned redox activities, photoreactivity, the availability of radioisotopes, and distinct spectroscopic signatures make them highly versatile scaffolds for the modulation, sensing, and imaging of biological processes. 2 Several years ago we established a research program exploring substitutionally inert metal-containing compounds as structural scaffolds for the design of enzyme inhibitors, and we demonstrated that ruthenium(II), 3 platinum(II), 4 osmium(II), 5 and iridium(III) 6 complexes, for example, can serve as highly potent and selective inhibitors of protein kinases and lipid kinases. 7 We believe that especially octahedral coordination modes offer new opportunities to design globular and well-defined molecular shapes that can fill protein pockets such as enzyme active sites in unique ways. 8 Our previous design was entirely based on the staurosporineinspired metallo-pyridocarbazole scaffold shown in Figure 1 , in which the maleimide moiety forms two key hydrogen bonds with the hinge region of the ATP-binding site, the pyridocarbazole heterocycle occupies the hydrophobic adenine binding cleft, and the remaining globular space-demanding octahedral or halfsandwich coordination sphere undergoes interactions in the region of the ribose-triphosphate binding site. 9 In this design strategy, the pyridocarbazole heterocycle-called "pharmacophore chelate ligand"-is rationally designed to interact with the hinge region of the ATP-binding site of protein kinases, whereas the remaining coordination sphere can then be established through combinatorial chemistry, structureÀactivity relationships, structurebased design, and combinations thereof. Although this approach turned out to be highly successful, we recently became interested in designing new pharmacophore chelate ligands for metalcontaining protein kinase inhibitors for two reasons: First, the synthesis of the pyridocarbazole ligand is lengthy and includes one photochemical step, thus complicating derivatizations in the course of structureÀactivity relationships and inhibitor scale-up reactions for in vivo studies. 10 Second, we envisioned that placing the metal center at a different position within the ATP-binding site might allow us to discover metal-containing inhibitors with very different binding profiles. In this respect it is noteworthy that protein kinases are among the largest enzyme families with more than 500 putative protein kinase genes, 11 and we estimate that our previous pyridocarbazole metal complex scaffold is probably only suitable for a subset of them. Here we now introduce 3-(2-pyridyl)-1,8-naphthalimide (1a; Scheme 1) as such a novel pharmacophore ligand. It can be synthesized in just three steps from readily available 1,8-naphthalic anhydride and coordinates to ruthenium in a bidentate fashion by activating a CÀH bond within the naphthalimide moiety, and as a proof of principle we report an organoruthenium complex which serves as a selective and nanomolar protein kinase inhibitor. ABSTRACT: A new metal-containing scaffold for the design of protein kinase inhibitors is introduced. The key feature is a 3-(2-pyridyl)-1,8-naphthalimide "pharmacophore chelate ligand", which is designed to form two hydrogen bonds with the hinge region of the ATP-binding site and is at the same time capable of serving as a stable bidentate ligand through CÀH activation at the 4-position of the electron-deficient naphthalene moiety. This CÀH activation leads to a reduced demand for coordinating heteroatoms and thus sets the basis for a very efficient three-step synthesis starting from 1,8-naphthalic anhydride. The versatility of this ligand is demonstrated with the discovery of a ruthenium complex that functions as a nanomolar inhibitor for myosin light-chain kinase (MYLK or MLCK).
' RESULTS AND DISCUSSION Synthesis of the 3-(2-Pyridyl)-1,8-naphthalimide Ligand. The synthesis of the 3-(2-pyridyl)-1,8-naphthalimide ligand 1a (R = H) and its benzylated derivative 1b (R = Bn), which merely served as a crystallization handle, is outlined in Scheme 1. Accordingly, a bromination of 1,8-naphthalic anhydride 2 in concentrated sulfuric acid using silver(I) sulfate as catalyst afforded exclusively 3-bromo-1,8-naphthalic anhydride (3; 91%), which was further converted to the free imide 4a (93%) or the benzylprotected imide 4b (71%) by treatment with concentrated ammonia or benzylamine, respectively. A subsequent Pd-mediated Stille cross coupling with 2-(trimethylstannyl)pyridine provided the final ligands 1a (67%) and 1b (99%) in three steps overall and total yields of 57% and 64%, respectively.
Synthesis of Half-Sandwich Compounds. To investigate the coordination properties of the new pyridylnaphthalimide ligands, we started with the synthesis of ruthenium half-sandwich complexes. For example, the reaction of the ligands 1a,b with [Ru(η 5 -C 5 H 5 )(CO)(MeCN) 2 ]PF 6 12 in the presence of Et 3 N at 60°C provided the complexes 5a (51%) and 5b (70%), which could be purified by standard silica gel flash chromatography (Scheme 2).
As anticipated, the CÀH activation occurred solely at the 4-position of the naphthalimide moiety, while no CÀH activation at the sterically more hindered 2-position was observed. A crystal structure of complex 5b is displayed in Figure 2 and confirms the bidentate binding of the ruthenium to the pyridine nitrogen (RuÀN = 2.09 Å) and the C-4 atom of the naphthalene moiety (RuÀC = 2.07 Å). It is worth noting that the facile CÀH activation and robustness of the formed RuÀC bond can be attributed to the highly electron deficient nature of the naphthalene moiety, being functionalized with electron-withdrawing pyridyl and maleimide substituents.
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Synthesis of Octahedral Complexes. In order to evaluate the synthesis of octahedral ruthenium complexes, ligand 1a was reacted with [Ru(MeCN) 3 ( [9] aneS 3 )](CF 3 SO 3 ) 2 14 ([9] aneS 3 = 1,4,7-trithiacylononane) and triethylamine in DMF at 60°C to obtain the monoacetonitrile complex 6 in 77% yield (Scheme 3). 
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This complex offers a quick access to different octahedral complexes by exchanging the remaining semilabile acetonitrile with other monodentate ligands. For example, heating the acetonitrile complex 6 under an atmosphere of CO for 3 h provided the CO complex 7 in 87% yield. The synthesis of the thiocyanate complex 8 and the selenocyanate complex 9 were accomplished by reacting complex 6 with NaSCN (23% yield) and KSeCN (30% yield), respectively. All three complexes were purified by regular silica gel flash chromatography. As an example, complex 7 was tested for its stability under biologically relevant conditions and was found to be stable in aqueous solution under air in the presence of millimolar concentrations of 2-mercaptoethanol for several days without any sign of decomposition, as determined by 1 H NMR spectroscopy. The crystal structure of complex 7 displayed in Figure 3 reveals that, in contrast to the half-sandwich complex 5b, the pyridylnaphthalimide ligand in the octahedral complex is twisted, which is apparently due to a steric repulsion between the CÀH group at the 5-position of the naphthalimide moiety and the sterically demanding 1,4,7-trithiacyclononane ligand. This steric repulsion also results in a significant distortion of the entire octahedral ruthenium coordination geometry. For example, the CO ligand is not oriented perpendicular to the plane of the naphthalimide moiety but instead is bent backward. Interestingly, the crystal structure furthermore demonstrates the desired ability of the imide moiety to form hydrogen bonds.
Synthesis of a Reactive "Precursor Complex". For future combinatorial chemistry it would be desirable to have access to a complex in which the ruthenium is coordinated to the pyridylnaphthalimide pharmacophore ligand in addition to labile monodentate coordinating ligands that can be replaced in a combinatorial fashion against other mono-, bi-, tri-, or even tetradentate ligands, thus providing rapid access to a diversity of novel structures just by straightforward ligand substitution chemistry. 15 In fact, the reaction of pyridylnaphthalimide 1a with [Ru(η 6 -C 6 H 6 )Cl 2 ] 2 in the presence of K 2 CO 3 and KPF 6 in refluxing acetonitrile afforded in one step the tetraacetonitrile complex 10 in a yield of 40% (Scheme 3). 16 The crystal structure of complex 10 is shown in Figure 4 . Despite the apparent lability of the four acetonitrile ligands, complex 10 is surprisingly robust and can be purified by regular silica gel flash chromatography. As expected, the acetonitrile ligands of 10 are prone to substitution at elevated temperature. For example, the reaction of 10 with 1,4,7-trithiacyclononane in DMF provided in a good yield of 73% the complex 6, in which three acetonitrile ligands have been replaced by 1,4,7-trithiacyclononane.
Protein Kinase Inhibition. To quickly gain insight into the protein kinase inhibition properties of pyridylnaphthalimide metal complexes, we tested complex 7 as a representative member of this class of compounds for its protein kinase binding affinity profile against the majority of the human protein kinases encoded in the human genome (human kinome). 11 This was accomplished Organometallics ARTICLE by using an active-site-directed competition binding assay with 442 different protein kinases (KINOMEscan, DiscoveRx) which provides primary data (%ctrl = percent of control: 0% = highest affinity, 100% = no affinity) that correlate with binding constants (K d ). 17, 18 Interestingly, out of the 442 enzymes tested, 8 protein kinases, namely CLK2, DMPK, HIPK2, MAP3K8, MYLK, PKCθ, RSK2, and RSK4, were identified as the main hits with %ctrl values below 0.1%. The human kinase dendrogram shown in Figure 5 reveals that these eight kinases are distributed among four protein kinase families. We selected myosin light-chain kinase (MYLK or MLCK) for further studies because MYLK plays a very important role in smooth muscle contraction. 19 Upon stimulation by agonists, the intracellular concentration of Ca 2+ of smooth muscle is elevated, causing Ca 2+ to bind to calmodulin. The complex of Ca 2+ and calmodulin then activates MYLK. We determined complex 7 to be a nanomolar inhibitor of MYLK with an IC 50 value (concentration of inhibitor at which the enzyme activity is reduced to 50%) of 75 ( 20 nM (100 μM ATP), which according to the ChengÀPrusoff equation (K m (ATP) = 50 μM) would reflect an inhibition constant (K d ) of approximately 25 nM. 20, 21 Surprisingly, the pyridylnaphthalimide ligand 1a itself does not show any sign of MYLK inhibition even at a concentration of 1 mM. Thus, the Ru(1,4,7-trithiacyclononane)(CO) fragment increases the binding affinity by more than 4 orders of magnitude. To evaluate if complex 7 binds as designed to the hinge region of the ATP-binding site, we synthesized a derivative of 7 in which the imide hydrogen is replaced by a methyl group (7Me). As shown in Figure 6 , this Organometallics ARTICLE methylation dramatically reduces the activity by almost 2 orders of magnitude (IC 50 = 5.2 ( 1.0 μM), consistent with the expectation that the imide hydrogen forms a hydrogen bond with a carbonyl oxygen of the hinge region, as indicated in Figure 1 . It is also worth noting that neither the half-sandwich complex 5a (IC 50 = 83 ( 36 μM) nor the thiocyanate 8 (IC 50 of 3.5 ( 0.9 μM) or selenocyanate 9 (IC 50 = 4.2 ( 1.3 μM) display any significant affinity for MYLK, indicating that it is the bent position of the coordinated CO that is crucial for MYLK binding, most likely through a specific interaction with a region of the flexible glycine-rich loop.
Acitivities in Human Cells. Finally, because of the recent clinical success of kinase inhibitors for the treatment of metastatic melanoma, 22, 23 we investigated complexes 5a and 7 as representative members of the new class of metallo-naphthalimides in an in vitro MTS proliferation assay 24 with two human-derived melanoma cell lines (451Lu and WM3918), as well as human melanocytes (FOM102010) and human fibroblast cells (FF2508) as controls ( Figure 7) . Unfortunately, even at a concentration as high as 20 μM, complex 7 did not show any significant effects on the melanoma or normal human cell lines (Figure 7a ). It can be assumed that this is due to the cationic nature of complex 7, which may prevent an efficient cellular uptake. In fact, in contrast to complex 7, the neutral complex 5a inhibited the proliferation of the melanoma cell lines 451Lu and WM3918 in a dosedependent fashion to 53% and 40% at 20 μM, respectively, while fibroblasts were only slightly affected and melanocytes not at all (Figure 7b ). Thus, due to this promising therapeutic window, complex 5a and derivatives thereof should be further evaluated for their antimelanoma activities.
' CONCLUSIONS In summary, we have introduced 3-(2-pyridyl)-1,8-napththalimide as a novel pharmacophore chelate ligand for metal-based protein kinase inhibitors and demonstrated its versatility by presenting a ruthenium complex as a nanomolar inhibitor of myosin light-chain kinase. 3-(2-Pyridyl)-1,8-naphthalimide is designed to interact with the hinge region of the ATP-binding site by forming two hydrogen bonds with the imide moiety. A key feature is its capability of serving as a stable bidentate ligand through CÀH activation at the 4-position of the electron-deficient naphthalene moiety, which simplifies the structure by reducing the number of required heteroatoms for transition-metal binding.
' EXPERIMENTAL SECTION General Methods. All reactions were carried out using oven-dried glassware and conducted under a positive pressure of nitrogen unless otherwise specified. 1,8-Naphthalic anhydride, silver(I) sulfate, and other chemicals were used as received from standard suppliers unless otherwise specified. 3-Bromo-1,8-naphthalic anhydride, 25 were prepared according to literature procedures. All solvents were distilled prior to use. Acetonitrile and DMF were dried by common methods and freshly distilled prior to use. NMR spectra were recorded on an Avance 300 (300 MHz), DRX-400 (400 MHz), Avance 500 (500 MHz), or DRX-500 (500 MHz) spectrometer. Infrared spectra were recorded on a Bruker Alpha FTIR instrument . High-resolution mass spectra were obtained with a Finnigan LTQ-FT instrument using either APCI or ESI. Complex 7Me was synthesized analogously to 7 (see the Supporting Information). 
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47 mmol) were dissolved in 15 mL of m-xylene, and the reaction mixture was purged with nitrogen for 15 min. Tetrakis(triphenylphosphine)-palladium(0) (197 mg, 0.17 mmol) was added and the mixture was heated to reflux for 22 h. After the mixture was cooled to ambient temperature, the solvent was removed and the crude product adsorbed onto silica gel, and subjected to silica gel chromatography with CH 2 Cl 2 / MeOH (75/1). The combined product eluents were dried in vacuo, and 3-(2-pyridyl)-1,8-naphtalimide (1a) was obtained as a pale yellow solid (0.63 g, 67% 
N-Benzyl-3-bromo-1,8-naphthalimide (4b). 3-Bromo-1,8-
naphthalic anhydride (3; 3.00 g, 10.8 mmol) was suspended in 75 mL of glacial acetic acid, benzylamine (1.78 mL, 16.2 mmol) was added, and the reaction mixture was heated to reflux for 18 h. The reaction mixture was carefully poured into ice-cold water, and the resulting beige precipitate was filtered off and washed with water. The crude product was dissolved in CH 2 Cl 2 , adsorbed onto silica gel, and subjected to silica gel chromatography with CH 2 Cl 2 /hexane (3/2). The combined product eluents were dried in vacuo to provide N-benzyl-3-bromo-1,8-naphtalimide (4b) as an off-white solid (2.82 g, 71%). 
N-Benzyl-3-(2-pyridyl)-1,8-naphthalimide (1b). N-Benzyl-
3-bromo-1,8-naphthalimide (4b; 417 mg, 1.14 mmol) and 2-(trimethylstannyl)pyridine (250 mg, 1.04 mmol) were dissolved in 25 mL of m-xylene, and the reaction mixture was purged with nitrogen for 15 min. Tetrakis(triphenylphosphine)palladium(0) (120 mg, 0.10 mmol) was added and the mixture heated to reflux for 22 h. After cooling to ambient temperature the solvent was removed, the crude product adsorbed onto silica gel, and subjected to silica gel chromatography with CH 2 Cl 2 /MeOH (75/1 to 35/1). The combined product eluents were dried in vacuo, and N-benzyl-3-(2-pyridyl)-1,8-naphthalimide (1b) was obtained as a pale yellow solid (381 mg, 99%). 1 6 (71 mg, 165 μmol) were dissolved in 5 mL of DMF and the reaction mixture was purged with nitrogen for 10 min. Following the addition of triethylamine (35 μL, 249 μmol), the mixture was heated to 60°C for 18 h. The reaction mixture was cooled to ambient temperature, diluted with 50 mL of CH 2 Cl 2 , and washed with saturated NH 4 Cl solution. The aqueous phase was washed with 2 Â 25 mL of CH 2 Cl 2 , the combined organic phases were dried using MgSO 4 , and the crude product was subjected to silica gel chromatography with CH 2 Cl 2 /MeOH (40/1). The combined product eluents were dried in vacuo, and the final complex 5a was obtained as a yellow solid (27 mg, 51% 2 ]PF 6 (28 mg, 66 μmol) were dissolved in 4 mL of DMF, and the reaction mixture was purged with nitrogen for 10 min. Following the addition of triethylamine (7.3 μL, 53 μmol), the mixture was heated to 60°C for 18 h. The solvent was removed and the crude product subjected to silica gel chromatography with CH 2 Cl 2 . The combined product eluents were dried in vacuo, and the complex 5b was obtained as an orange solid (18 mg, 70%). 2 (269 mg, 383 μmol) were dissolved in 5 mL of DMF, triethylamine (92 μL, 663 μmol) was added, and the reaction mixture was heated to 60°C for 14 h. The solution was cooled to ambient temperature, the solvent was removed, and the crude product was subjected to silica gel chromatography, first with acetonitrile, followed by acetonitrile/water/saturated KNO 3 solution (50/3/1). The combined product eluents were dried in vacuo, the residue was dissolved in a minimal amount of acetonitrile/ water, and NH 4 PF 6 was added. The solution was centrifuged, and the resulting orange filter cake was washed three times with water and dried in vacuo to provide the monoacetonitrile 6 complex as an orange solid (145 mg, 77%). Method b. Tetraacetonitrile complex 10 (15 mg, 22 μmol) was dissolved in 3 mL of DMF, 1,4,7-trithiacyclonane was added, and the mixture was heated to 90°C for 24 h. The solution was cooled to ambient temperature, the solvent was removed, and the crude product was subjected to silica gel chromatography, first with acetonitrile followed by acetonitrile/water/saturated KNO 3 solution (50/3/1). The combined product eluents were dried in vacuo, the residue was dissolved in a minimal amount of acetonitrile/water, and NH 4 PF 6 was added. The solution was centrifuged, and the resulting orange filter cake was washed three times with water and dried in vacuo to provide monoacetonitrile complex 6 as an orange solid (12 mg, 73%) . 1 Complex 7. The monoacetonitrile complex 6 (15 mg, 20 μmol) was dissolved in 4 mL of DMF and purged with CO gas for 30 s. The solution was heated to 95°C for 3 h. The solvent was removed and the crude product subjected to silica gel chromatography, first with acetonitrile followed by acetonitrile/water/saturated KNO 3 solution (50/3/1). The combined product eluents were dried in vacuo, the residue was dissolved in a minimal amount of acetonitrile/water, and NH 4 PF 6 was added. The solution was centrifuged, and the resulting yellow filter cake was washed three times with water and dried in vacuo to provide monoacetonitrile complex 7 as a yellow solid (13 mg, 87%). Complex 9. The monoacetonitrile complex 6 (16 mg, 22 μmol) was dissolved in 2 mL of DMF, KSeCN (5 mg, 32 μmol) in water (100 μL) was added, and the solution was heated to 95°C for 12 h. The solvent was removed and the crude product subjected to silica gel chromatography with CH 2 Cl 2 /MeOH (gradient 20/1 to 10/1). The combined product eluents were dried in vacuo, and the selenocyanate complex 9 was obtained as a red solid (4 mg, 30%). The ruthenium coordination of the ambidente SeCN ligand through selenium was verified by the crystal structure of a benzylated derivative (see the Supporting Information). Reactions were performed with a total volume of 25 μL. After 45 min, the reaction was terminated by spotting 15 μL on a circular P81 phosphocellulose paper (2.1 cm diameter, Whatman), followed by washing three times with 0.75% phosphoric acid and once with acetone. The dried P81 papers were transferred to a scintillation vial, 5 mL of scintillation cocktail was added, the counts per minute (CPM) were measured with a Beckmann Coulter TM LS6500 Multi-Purpose Scintillation Counter, and the IC 50 values were defined to be the concentration of inhibitor at which the counts per minute (CPM) were 50% of the control sample, corrected by the background CPM.
Cell Viability Assays. Human melanoma cell lines (451Lu, WM3918) were isolated as previously described 29 and were further cultured in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum. Normal human primary melanocytes (FOM102010) and fibroblasts (FF2508) were isolated from the human epidermis of neonatal foreskins and cultured as described. 30, 31 Cells (5000/well) were seeded in 96-well plates and allowed to adhere overnight. The following day, complex 5a, 7, or DMSO vehicle control was added to the cells at different concentrations and the cells were incubated for another 96 h. Cells were then directly incubated with MTS substrate (CellTiter-96 Aqueous One Solution Cell Proliferation Assay, Promega). 24 The absorbance was measured at 490 nm as per the supplier's instructions, and the percent proliferation was normalized to the absorbance of DMSO-treated cells. For each cell line and treatment, the absorbance values of at least 4 wells were used to analyze the data.
Single-Crystal X-ray Diffraction Studies. The intensity data sets for all compounds were collected at 100 K using a STOE IPDS2 (5b) or IPDS-2T (7, 10) system. The data were corrected for absorption effects using multiscanned reflections (5b) 32 or indexed faces (7, 10), 33 respectively. The structures were solved using direct methods (SIR-92 34 for 10 and SIR2008 35 for 5b, 7) and refined using the full-matrix leastsquares procedure implemented in SHELX-97. 36 Hydrogen atoms were included at calculated positions, N-bonded H atoms in 10 were located and refined isotropically. The crystal of 5b was twinned. Only the reflections of one twin domain were used for refinement. In 5b two positions of a disordered CH 2 Cl 2 molecule were refined with a total occupation of 0.65 in the asymmetric unit. In 7 one hexafluorophosphate anion was disordered. High displacement factors indicate non esolved disorder of the solvent ether molecules. Crystallographic data for 5b, 7, and 10 are given in Table 1 .
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